Skip to content

Sulfur 7% Cream Compared With Permethrin 5% Cream for Treating Scabies in Adults

Cure, Sleep and Treatment Satisfaction With Topical Sulfur 7% Versus Permethrin 5% in Scabies: A Randomized Open-Label Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07822672
Enrollment
90
Registered
2026-09-16
Start date
2024-06-01
Completion date
2026-06-01
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scabies

Keywords

Scabies, sulfur, pruritus, sleep, treatment satisfaction, permethrin, randomized controlled trial

Brief summary

This study compares two creams used to treat scabies, a common skin condition caused by mites that causes intense itching. Ninety adults with scabies were randomly assigned to receive either sulfur 7% cream or permethrin 5% cream. Sulfur cream was applied once each evening for three nights in a row; permethrin cream was applied once, left on overnight, and repeated after one week. Participants were examined after two weeks and again after four weeks to see whether the scabies had cleared. The study also looked at how quickly itching improved, how much sleep improved, how satisfied participants were with each treatment, how many side effects occurred, and how much each treatment cost. The goal is to help doctors and patients choose between these two widely available, inexpensive treatments based on real-world evidence of how well each one works and how well it is tolerated.

Detailed description

Scabies is a highly pruritic skin infestation caused by Sarcoptes scabiei that remains endemic in many resource-limited settings. Permethrin 5% cream is recommended as first-line topical therapy in most international guidelines, but sulfur-based preparations remain widely used because of their low cost and long safety record, particularly in settings where permethrin is expensive or unavailable. Head-to-head comparative data between these two agents, especially data incorporating patient-centered outcomes such as sleep and treatment satisfaction, are limited. This was a randomized, open-label trial conducted at Can Tho Dermatology Hospital, Can Tho City, Vietnam, enrolling 90 adults aged 18 years or older with a clinical diagnosis of ordinary (non-crusted) scabies, established using the 2020 International Alliance for the Control of Scabies (IACS) consensus criteria. Participants were randomly allocated in a 1:1 ratio to one of two treatment arms. In the sulfur arm, sulfur 7% cream was applied from the neck to the soles each evening, left on for 8-14 hours, and washed off, for three consecutive days. In the permethrin arm, permethrin 5% cream was applied in the same manner as a single overnight application, repeated once after seven days. Both groups received standardized instructions on decontamination of clothing, bedding and towels, and household contacts were offered the same regimen. Participants were evaluated at baseline, week 2, and week 4. The primary outcome was complete cure, defined according to the 2017 European guideline as resolution of pruritus with no active or new lesions on examination. Secondary outcomes included pruritus severity (verbal rating scale), sleep quality and insomnia symptoms (Athens Insomnia Scale), treatment satisfaction (9-item Treatment Satisfaction Questionnaire for Medication), adverse events, and direct treatment cost. Associations between improvement in itching and improvement in sleep were also examined. Because outcome data were not normally distributed, between-group and within-group comparisons used non-parametric methods (Mann-Whitney U, Wilcoxon signed-rank, chi-square or Fisher's exact test, and Spearman rank correlation).

Interventions

DRUGSulfur 7% cream

Applied from neck to soles once each evening, left on for 8-14 hours then washed off, for 3 consecutive days.

DRUGPermethrin 5% cream

Applied from neck to soles as a single overnight application (8-14 hours), repeated once after 7 days.

Sponsors

Can Tho University of Medicine and Pharmacy
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 years or older * Clinical diagnosis of ordinary (non-crusted) scabies, established using the 2020 International Alliance for the Control of Scabies (IACS) consensus criteria, category B: * B1: burrow identified, or * B2: typical lesions at male genitalia, or * B3: typical lesions at typical sites plus pruritus and a history of close contact with a person with scabies or itch

Exclusion criteria

* Known allergy or intolerance to sulfur or permethrin * Pregnant or breastfeeding women * Hearing, visual, or cognitive impairment preventing reliable self-reporting of symptoms * Self-discontinuation of study treatment before completion

Design outcomes

Primary

MeasureTime frameDescription
Complete cure rate at week 2Week 2 after treatment initiationProportion of participants achieving complete cure using the same definition as above, assessed at the earlier time point.
Complete cure rate at week 4Week 4 after treatment initiationProportion of participants achieving complete cure, defined per the 2017 European guideline as resolution of pruritus with no active lesions and no new lesions on clinical examination.

Secondary

MeasureTime frameDescription
Change in pruritus severityBaseline, week 2, week 4Change in itching intensity measured by a verbal rating scale (0-4).
Change in insomnia symptoms (Athens Insomnia Scale)Baseline, week 2Change in sleep disturbance measured by the Athens Insomnia Scale (AIS, 8 items, range 0-24; higher scores indicate worse insomnia).
Insomnia prevalenceBaseline, week 2Proportion of participants meeting the AIS cutoff for clinically significant insomnia.
Treatment satisfactionWeek 4Treatment satisfaction measured by the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), scored across three domains (effectiveness, convenience, global satisfaction; each 0-100, higher scores indicating greater satisfaction).
Incidence of treatment-related adverse eventsThrough week 4Proportion of participants experiencing adverse events attributable to study cream (e.g., skin burning, irritation, contact dermatitis).
Direct treatment costWeek 4Direct cost of the treatment course per participant, converted to US dollars.
Correlation between itch reduction and sleep improvementWeek 2Spearman correlation between reduction in pruritus score and improvement in AIS score from baseline to week 2.

Countries

Vietnam

Contacts

PRINCIPAL_INVESTIGATORTran Gia Hung, PhD

Can Tho University of Medicine and Pharmacy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026